Los puntos clave no están disponibles para este artículo en este momento.
ful marketing, particularly since the market leaders in many countries were drugs with no evidence of benefits in mortality at the time. This may also explain in part why the heaviest use was in France, which had relatively low cardiovascular mortality even before statins were available. Political, cultural, and social issues determine such use as well as medical indications. In view of the public health implications, these merit more specific study in each country.
Toelle et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: